Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Intangibles (2018 - 2022)

Summit Therapeutics' Intangibles history spans 5 years, with the latest figure at $8.0 million for Q3 2022.

  • For Q3 2022, Intangibles fell 25.04% year-over-year to $8.0 million; the TTM value through Sep 2022 reached $8.0 million, down 25.04%, while the annual FY2021 figure was $10.4 million, 9.69% down from the prior year.
  • Intangibles reached $8.0 million in Q3 2022 per SMMT's latest filing, down from $8.9 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $19.9 million in Q1 2018 to a low of $8.0 million in Q3 2022.
  • Average Intangibles over 5 years is $11.6 million, with a median of $11.1 million recorded in 2020.
  • Peak YoY movement for Intangibles: plummeted 31.78% in 2019, then fell 4.44% in 2021.
  • A 5-year view of Intangibles shows it stood at $19.9 million in 2018, then tumbled by 35.8% to $12.8 million in 2019, then decreased by 9.99% to $11.5 million in 2020, then dropped by 9.69% to $10.4 million in 2021, then dropped by 23.53% to $8.0 million in 2022.
  • Per Business Quant, the three most recent readings for SMMT's Intangibles are $8.0 million (Q3 2022), $8.9 million (Q2 2022), and $9.9 million (Q1 2022).